Analyst Ratings for [VSTM] Verastem, Inc.

12/31/24	Reiterated	Buy	X
VSTM Verastem BTIG Research
$13 $20
9/30/24	Initiated	Buy	X
VSTM Verastem Guggenheim
$13
11/21/23	Resumed	Buy	X
VSTM Verastem BTIG Research
$27
9/27/23	Initiated	Buy	X
VSTM Verastem B. Riley Securities
$21
6/15/23	Upgrades	Neutral Buy	X
VSTM Verastem Mizuho
$24 $36
9/7/22	Resumed	Buy	X
VSTM Verastem Alliance Global Partners
$6
4/29/22	Resumed	Overweight	X
VSTM Verastem Cantor Fitzgerald
$6 $5
4/14/22	Initiated	Outperform	X
VSTM Verastem RBC Capital Mkts
$5
3/9/22	Initiated	Buy	X
VSTM Verastem Truist
$6
7/1/21	Initiated	Buy	X
VSTM Verastem Alliance Global Partners
$6
6/20/19	Downgrades	Buy Neutral	X
VSTM Verastem BTIG Research
5/10/19	Downgrades	Outperform Mkt Perform	X
VSTM Verastem Raymond James
7/13/18	Initiated	Buy	X
VSTM Verastem BTIG Research
$17
5/2/18	Initiated	Buy	X
VSTM Verastem Seaport Global Securities
$14
3/8/18	Initiated	Buy	X
VSTM Verastem B. Riley FBR, Inc.
$15

VSTM Verastem, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.